Sanford C. Bernstein set a €115.00 ($136.90) target price on Merck KGaA (FRA:MRK) in a report released on Wednesday. The firm currently has a buy rating on the healthcare company’s stock.

Other equities analysts also recently issued research reports about the company. Commerzbank set a €103.00 ($122.62) price objective on Merck KGaA and gave the stock a neutral rating in a report on Thursday, October 26th. Oddo Bhf set a €125.00 ($148.81) price objective on Merck KGaA and gave the stock a buy rating in a report on Friday, October 27th. DZ Bank restated a neutral rating on shares of Merck KGaA in a report on Tuesday, November 14th. JPMorgan Chase & Co. set a €100.00 ($119.05) price objective on Merck KGaA and gave the stock a neutral rating in a report on Friday, September 29th. Finally, Citigroup set a €123.00 ($146.43) price objective on Merck KGaA and gave the stock a buy rating in a report on Monday, October 2nd. Twelve analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has an average rating of Hold and an average target price of €107.57 ($128.06).

Merck KGaA (FRA:MRK) opened at €89.66 ($106.74) on Wednesday. Merck KGaA has a twelve month low of €87.33 ($103.96) and a twelve month high of €115.00 ($136.90). The company has a market capitalization of $11,650.00 and a P/E ratio of 21.00.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/sanford-c-bernstein-analysts-give-merck-kgaa-mrk-a-115-00-price-target/1814865.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.